Related by context. All words. (Click for frequent words.) 77 squalamine 74 trodusquemine MSI 70 EVIZON TM 67 EVIZON TM squalamine lactate 65 synthetic retinoid 64 rheumatoid arthritis thrombocytopenia 64 Hedgehog pathway inhibitor 64 non nucleoside HCV 64 inflammatory autoimmune diseases 64 Immunotherapeutic 63 anthrax monoclonal antibody 63 sodium Injection 63 apricitabine ATC 63 POSIDUR TM ELADUR TM 62 oral prodrug 62 DNA RNA Medicines 62 PNP inhibitor 62 peramivir clinical trials 62 CYT# potent vascular disrupting 62 lintuzumab SGN 62 receptor tyrosine kinase inhibitor 61 TELINTRA 61 SinuNase ™ 61 JAK2 inhibitor 61 JZP 61 IIb clinical trial 61 vaginally administered lidocaine 61 AAG geldanamycin analog 61 MEK inhibitor 61 Phase #b/#a clinical 61 oral methylnaltrexone 61 Phase IIa clinical trials 61 candidate XP# 61 Protexia ® 61 PDE4 inhibitor 61 OMNARIS HFA 61 Begins Dosing 61 targeted radiotherapeutic 61 Phase IIb clinical trials 60 Lenocta TM 60 XL# XL# XL# XL# 60 Asentar TM 60 alvespimycin 60 treat opioid induced 60 novel VDA molecule 60 HDAC Inhibitor 60 CDAD Clostridium difficile 60 mGluR2 positive 60 peramivir BCX 60 Phase IIb trials 60 aurora kinase 60 HCD# [002] 60 forodesine 60 orally administered inhibitor 60 Fodosine TM BCX 60 Xyfid TM 60 telomerase inhibitor drug 60 Genasense ® oblimersen 60 recombinant biopharmaceutical 60 vaccine GRNVAC1 60 phase IIa 60 FOLOTYN ® 60 TACI Ig 60 CDK cyclin dependent 60 Tarsa Therapeutics 60 Phase 2a clinical trials 59 ALN PCS 59 incyclinide 59 Hedgehog antagonist 59 refractory chronic lymphocytic 59 generation purine nucleoside 59 phase IIb clinical 59 XL# anticancer compounds 59 TKM ApoB 59 HCV polymerase 59 TRANSDUR TM Sufentanil 59 mGluR5 negative 59 ELADUR ™ 59 Neo Kidney Augment 59 HCV polymerase inhibitor 59 IL# PE#QQR 59 Onalta ™ 59 Bicifadine 59 huC# DM4 59 histone deacetylase HDAC inhibitor 59 RELOVAIR ™ 59 dasatinib Sprycel ® 59 glucokinase activator 59 TOCOSOL Paclitaxel 59 non nucleoside inhibitor 59 Hsp# chaperone system 59 Zenvia ™ 59 XP# XP# 59 CORLUX CORT # 59 sitaxsentan 59 XOMA 3AB 59 MAb therapy 59 Allovectin 7 R 59 elotuzumab 59 investigational humanized monoclonal antibody 59 PEG SN# 59 molecular imaging radiopharmaceutical 59 iii GTx 59 antibody MAb 59 CEQ# 59 BLA filing 58 omecamtiv mecarbil formerly 58 Phase IIb Trial 58 cutaneous T 58 MCSP respectively 58 5 HT2A inverse 58 Certolizumab 58 PANVAC VF 58 SinuNase TM 58 confirmatory Phase III 58 Aerosurf 58 oral calcitonin 58 acyclovir Lauriad R 58 LymphoStat B belimumab 58 MEK Inhibitor 58 MAXY alpha 58 Allovectin 7 58 AVN# [001] 58 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 58 tezampanel NGX# 58 mGluR2 NAM 58 selective androgen receptor modulator 58 PLK1 SNALP 58 keloid scarring 58 Prodarsan R 58 REMOXY R 58 HuLuc# 58 novel histone deacetylase 58 CB2 selective receptor agonist 58 RhuDex ® 58 lexidronam injection 58 Phase IIa trials 58 R lenalidomide 58 hypoxia activated prodrug 58 Testosterone MDTS ® 58 CORT # 58 octreotide implant 58 GALNS 58 IAP inhibitor 58 HGS# 58 ALVESCO R 58 trastuzumab DM1 T DM1 58 CD# CEA 58 treat dysmenorrhea 58 ADP receptor antagonist 58 Completes Patient Enrollment 58 Cleviprex TM clevidipine 58 midstage trials 58 #D#C# 57 Tanespimycin 57 talactoferrin 57 Genasense oblimersen sodium Injection 57 evaluating satraplatin 57 CK # novel 57 Cetrorelix 57 Kamada AAT 57 herpes zoster shingles 57 forodesine HCl 57 Genasense R oblimersen 57 virus HCV protease inhibitor 57 Phase 2b Clinical Trial 57 allosteric modulator NAM 57 TransVax 57 TLK# 57 TYZEKA 57 JAK inhibitor 57 Surfaxin LS 57 JOULFERON 57 CDP# 57 HuMax TAC 57 Phase IIIb clinical 57 Phase 2a clinical 57 Ocrelizumab 57 treat lupus renal 57 Plicera 57 Silodosin 57 anti CD3 monoclonal 57 Nicotine Conjugate Vaccine 57 TRANSDUR ™ 57 Phase 2a trial 57 Certolizumab pegol 57 tramiprosate Alzhemed TM 57 Aurora kinase inhibitor 57 lucinactant 57 MAGE A3 ASCI 57 dependent kinase inhibitor 57 Hematide ™ 57 Allovectin 7 ® 57 Initiate Phase 57 ARRY # 57 delta opioid receptor 57 AMEVIVE 57 ISTODAX 57 lomitapide 57 catheter occlusion 57 P#X# antagonist 57 Vascular Disrupting Agent 57 AIMM trial 57 Prodarsan 57 Locteron exclusively 57 Hedgehog agonist 57 Pivotal Phase III 57 Panzem R 57 VEGFR2 inhibitor 57 prokinetic agent 57 including eniluracil ADH 57 PRECISE Trial 57 2A receptor agonist 57 mertansine 57 Phase #/#a trial 57 ALTROPANE R 57 tiapamil 57 mitogen activated ERK kinase 57 ALN TTR# 57 sorafenib tablets 57 Curaxin CBLC# 57 LymphoStat B TM 57 Phase Ib clinical trials 57 AERx ® 57 novel therapeutic antibodies 57 dyskinesia PD LID 57 IAP inhibitors 57 JAK1 57 Phase III Clinical Trial 57 recurrent glioblastoma multiforme 57 RNAi therapeutic targeting 57 Shigamabs ® 57 acetonide FA 56 oral nucleoside analogue 56 NDA Submission 56 Xanafide 56 ocrelizumab 56 ALN TTR 56 Fibrillex TM 56 adecatumumab MT# 56 dextromethorphan quinidine 56 GLP toxicology studies 56 Cloretazine ® 56 phase Ib clinical 56 PEGylated interferon 56 alagebrium 56 evaluating pirfenidone 56 Nuvion 56 telaprevir VX 56 NYSE Amex PTN 56 ONCONASE R 56 HCV protease inhibitor 56 GTC recombinant human 56 Evoltra ® 56 bile duct tumor 56 IMC #B 56 TBC# 56 Elagolix 56 histone deacetylase HDAC 56 Treatment IND 56 EGS# 56 TKB# 56 HepeX B 56 maribavir 56 TP# CETi 1 56 Initiates Phase III 56 PSN# [002] 56 ketolide antibiotic 56 Besivance 56 highly purified pasteurized 56 ThermoDox ® clinical 56 Alzhemed TM 56 cell lymphoma CTCL 56 Intravenous Human 56 histamine dihydrochloride 56 BioSante licensees 56 phase IIb trial 56 visilizumab 56 TM pralatrexate injection 56 fostamatinib 56 Factor VIIa 56 Anturol TM 56 Genasense ® 56 alkylating agent 56 #beta HSD1 56 Personalized Immunotherapy 56 Nasdaq PGNX today 56 AQ4N 56 Lovaxin C 56 ASONEP 56 AGILECT R 56 Bezielle 56 Luveniq 56 Panzem R NCD 56 ThermoDox R 56 N acetylgalactosamine 6 56 systemically administered 56 Solazed TM 56 anticancer compound 56 pralatrexate injection folate analogue 56 JAK2 Inhibitor 56 bevirimat Study 56 RAPTIVA R 56 Phase III Pivotal 56 next generation URAT1 56 Spiegelmer ® 56 PHX# 56 Maxy G# 56 Initiates Phase II 56 nalbuphine ER 56 Diamyd ® 56 InterfeRx 56 glucagon receptor 56 MT#/MEDI-# 56 NEBIDO R 56 TNFerade TM 56 volociximab 56 hepatitis B HBV 56 MOVIPREP R 56 Phase 1b clinical trials 56 TRIOLEX HE# APOPTONE HE# 56 samarium Sm 56 VEGF Trap 56 methylnaltrexone bromide 56 Allovectin 7 r 56 R Rituximab Herceptin 56 Phenoptin 56 Pafuramidine 56 phase IIb study 56 severe hypercholesterolemia 56 PF # [002] 56 TRO# 56 Hsp# Inhibitor 55 Zenvia TM 55 polycythemia vera essential thrombocythemia 55 Successfully Completes Phase 55 SILENOR TM 55 Sulonex TM 55 Initiates Enrollment 55 Proellex TM 55 ZFN TM 55 HuMax CD4 55 Telintra 55 include Ischemic Paraplegia 55 IND enabling 55 IFN Beta CTP 55 intranasal formulation 55 Solzira TM 55 Nasdaq HALO 55 NasdaqGM NTEC today 55 Kit CD# positive 55 initiated Phase Ib 55 HCV SPRINT 55 KNS # 55 Preclinical studies suggest 55 compound PMX # 55 HIV integrase inhibitors 55 fosbretabulin 55 cinacalcet HCl 55 StaphVAX R 55 REMOXY ® 55 Aflibercept 55 APEX PD 55 IIa trial 55 huN# DM1 55 nicotinic alpha 7 55 LEUKINE 55 TransVax ™ 55 reslizumab 55 MOR# 55 SPRYCEL ® 55 Staphylococcus aureus Polysaccharide Conjugate 55 evaluating mipomersen 55 PULSYS 55 oral NKTR 55 EDEMA3 trial 55 post herpetic neuralgia PHN 55 liposomal formulation 55 novel L DOS# 55 AzaSite Plus 55 UVIDEM 55 allosteric modulator PAM 55 Inc. Nasdaq CYCC 55 Hepatitis C HCV 55 intravesical infusion therapy 55 GTC recombinant form 55 methylnaltrexone 55 ospemifene 55 oral PTH 55 PrevOnco 55 hepatitis C HCV 55 Archexin 55 Achieves Primary Endpoint 55 HepeX B TM 55 advanced unresectable 55 TRANSDUR ® 55 alpha 2A 55 compound INCB# 55 CancerVax Corporation 55 QLT# 55 cMET 55 Prodarsan ® 55 ELACYT 55 VQD 55 R roscovitine CDK cyclin 55 novel proprietary KL4 55 NS5A 55 GATTEX ® 55 treat chronic sinusitis 55 please visit www.advaxis.com 55 Behcet uveitis 55 lenalidomide Revlimid R 55 candidate Zenvia 55 Phase Ib study 55 induced macular edema 55 Zorbtive TM 55 Protexia R 55 VIVITROL ® 55 inhaled liposomal ciprofloxacin 55 Abiraterone acetate 55 Staccato loxapine 55 Omacetaxine 55 Amoxicillin PULSYS 55 initiated Phase 1b 55 R#/MEM # 55 PentaStaph 55 nonhematologic adverse reactions 55 Acetavance TM 55 brivaracetam 55 Urocortin 2 55 Belimumab 55 INSPIRE Trial Phase III 55 cathepsin K inhibitor 55 candidate deforolimus 55 targeting PCSK9 55 Rhucin ® recombinant 55 Tamibarotene 55 anti botulism antibody 55 Simulect 55 eniluracil 55 AEG# 55 ApoB SNALP 55 Enkephalin 55 Virulizin ® 55 Daclizumab 55 evaluating tivozanib 55 vidofludimus 55 structure infections ABSSSI 55 Tarceva TM 55 Anidulafungin 55 ancrod 55 systemic anaplastic large 55 compound KOS 55 Phase 2a Study 55 VP# [004] 55 5 lipoxygenase inhibitor 55 Zenvia Phase III 55 arsenic trioxide injection 55 posaconazole 55 ADVEXIN p# therapy 55 sapropterin dihydrochloride 55 OvaRex ® MAb 55 Canvaxin TM 55 Troxatyl 55 budesonide foam 55 EVIZON 55 refractory gout 55 immunosuppressive compound 54 severe oral mucositis 54 oral proteasome inhibitor 54 candidate WF# 54 drug pipeline TAFA# 54 PROMACTA 54 RSD# oral 54 GATTEX ™ 54 Testosterone MDTS R 54 myeloproliferative diseases 54 MIST II 54 TYGACIL 54 Initiates Clinical 54 PEGPH# 54 CTA# Injection 54 BENLYSTA ® 54 miconazole Lauriad R 54 bardoxolone 54 GAMMAGARD 54 BRIM3 54 diarrhea predominant irritable 54 muscarinic 54 oxymorphone ER 54 outlicensing 54 UPLYSO 54 HCV RESPOND 2 54 Panzem ® 54 BiTE R 54 ACTEMRA TM 54 Nasdaq PPHM 54 Lenocta 54 Pharmos pipeline 54 Pivotal Phase 54 Dacogen injection 54 TELCYTA 54 Cethrin 54 postherpetic neuralgia PHN 54 ATL# [001] 54 TRX1 54 preclinical toxicology 54 Hodgkin lymphoma HL 54 Nasdaq MBRX 54 PrevOnco ™ 54 valtorcitabine 54 gallium nitrate injection 54 developing ACAPODENE 54 GnRH antagonist 54 SAR# [004] 54 PDX pralatrexate 54 Dose adjustments 54 potently inhibit 54 MORAb 54 Solazed 54 inverse agonist 54 romazarit 54 Pharmacopeia Phase 54 BRIM2 54 unique alkylating agent 54 memantine HCl 54 pseudobulbar affect PBA 54 pentostatin 54 Luramist 54 Liprotamase 54 Hepatocellular Carcinoma HCC 54 novel emulsion formulation 54 Alfimeprase 54 MethyPatch 54 oral salmon calcitonin 54 REVIVE Diabetes 54 Xcytrin R 54 Cannabinor 54 please visit www.middlebrookpharma.com 54 LHRH antagonist 54 non alcoholic steatohepatitis 54 gemcitabine Gemzar ® 54 CD# monoclonal antibody 54 PREOS R 54 PEGINTRON TM 54 phase IIb 54 Cethromycin 54 ATL/TV# 54 human C1 inhibitor 54 PI3K/Akt pathway inhibitor 54 humanized anti 54 NASDAQ IDEV 54 Meets Primary Endpoint 54 SUPPRELIN R LA 54 investigational oral inhibitor 54 phase IIa clinical 54 ganetespib 54 Sphingomab TM 54 ASONEP TM 54 Aryplase 54 lipoprotein lipase deficiency LPLD 54 immunotherapeutic vaccine 54 Solazed ™ 54 generation URAT1 inhibitor 54 brivanib 54 atacicept 54 AKT inhibitor 54 initiate Phase IIa 54 EvaMist TM 54 PRX # 54 budesonide MMX Phase III 54 opioid induced bowel dysfunction 54 Combination REOLYSIN R 54 DIFICID ™ 54 PRTX 54 confirmatory Phase 3 54 proprietary Capillary Aerosolization Technology 54 candidates bavituximab 54 Ridaforolimus 54 dirucotide 54 Complicated Skin 54 GSK# [001] 54 Nasdaq VRTX 54 Randomized Phase 54 erlotinib Tarceva ® 54 evaluating picoplatin 54 EpiCept NP 1 54 Phase #b/#a trial 54 TELINTRA R 54 Hedgehog Pathway Inhibitor 54 Glufosfamide 54 lead Aganocide compound 54 humanized monoclonal antibody 54 Crofelemer budesonide foam 54 ZEGERID Chewable Tablets 54 Exelixis XL# 54 Phase 2a Trial 54 Urocidin TM 54 Cimzia TM 54 IgG1 monoclonal antibody 54 PDE# inhibitors 54 dextofisopam 54 Phase 2b clinical trials 54 SUTENT ® 54 CEL SCI Phase III 54 PDL# 54 EVIZON ™ 54 developing ostarine selective 54 CytoFabTM 54 Exherin TM 54 NGX# 54 Nexavar sorafenib 54 cannabinor 54 dihydrochloride Tablets 54 Iluvien ® 54 IMA# 54 personalized cellular immunotherapy 54 Phase IIb III 54 drug GAP #B# 54 PEG PAL 54 MyVax R 54 HIV integrase inhibitor 54 Alinia 54 PROMACTA CARES 54 PRNewswire FirstCall Genta Incorporated 54 Phase IIB 54 investigational antiplatelet agent 54 Submits NDA 54 EGFR HER2 54 INCB# [001] 54 orBec ® oral beclomethasone 54 PROLACRIA ™ 54 Nasdaq XTLB 54 Raptiva ® 54 Maribavir 54 Phase IIb Clinical Trial 54 CCR9 antagonist 54 oral ridaforolimus 54 Androxal TM 54 ZFP Therapeutics 54 Dupuytren Contracture 54 HQK 54 Seliciclib CYC# 54 Prosaptide 54 Stimuvax R 54 HER2 positive metastatic breast 53 Glybera 53 investigational oral hepatitis C 53 NASDAQ PGNX 53 Traficet EN 53 alpha 2A adrenoceptor 53 PXD# 53 Inc. AMEX YMI 53 teduglutide 53 patient derived xenografts 53 ATryn R 53 multicenter Phase 53 vapreotide acetate 53 IND submission 53 tivozanib AV 53 website www.celsion.com 53 novel synthetic PEGylated 53 thrombin inhibiting aptamer 53 Phase 1a clinical 53 PSMA ADC 53 Ketotransdel 53 phase Ib 53 riociguat 53 % uracil topical 53 rufinamide 53 bevasiranib 53 Urocidin 53 Bevasiranib 53 Capesaris 53 Civacir 53 CIMZIA TM 53 TKM Ebola 53 Amigal 53 Soliris TM eculizumab 53 Veronate 53 CR# vcMMAE 53 demonstrated antitumor activity 53 Icatibant 53 interferon gamma 1b 53 WX UK1 53 Lixivaptan 53 product platforms AZX# 53 Phase Ib IIa 53 Belinostat 53 EMSAM 53 CMV vaccine 53 Ofatumumab 53 ROTATEQ 53 extensively metabolized 53 LEP ETU 53 CholeraGarde R Peru 53 HuMax EGFr 53 apoptosis proteins 53 AZX# 53 naronapride 53 Phase Ib clinical 53 RAPTIVA 53 haematologic 53 Phase IIb trial 53 Clevudine 53 tanespimycin 53 Pivotal Trial 53 treatment naive genotype 53 TKM PLK1 53 selective A2A adenosine receptor 53 Ostarine TM 53 dirucotide MBP# 53 Generx TM 53 dacetuzumab 53 Ganite ® 53 rhIGF-I/rhIGFBP-3 53 Auxilium anticipates 53 registrational trial 53 BCX# 53 Cloretazine 53 Golimumab 53 torsemide ER 53 POSIDUR TM 53 Aviptadil 53 Fast Track Status 53 oral ghrelin agonist 53 HCV NS5B polymerase 53 IKK beta 53 PEG Interferon lambda 53 Intraject 53 Phase Ib II 53 mGluR2 mGluR4 mGluR5 mGluR7 53 alpha antagonist 53 Onalta 53 Methylnaltrexone 53 Fodosine 53 investigational hepatitis B 53 ENRICH trial 53 preclinical studies 53 Nasdaq DVAX 53 trastuzumab Herceptin R 53 Receives Milestone Payment 53 successfully commercialize Iluvien 53 TMC# [002] 53 Cloretazine R 53 Canvaxin 53 LUMINATE 53 systemic ALCL 53 multicenter Phase II 53 CoTherix logo 53 Regeneron Pharma 53 Prestara 53 apoptosis inducer 53 Patient Enrollment 53 dexanabinol 53 Dextofisopam 53 senicapoc 53 CCR5 mAb 53 Phase Ia 53 SonoLysis 53 Phase IIa Clinical Trial 53 ALN HTT 53 GED aPC 53 Brentuximab Vedotin SGN 53 ularitide 53 Cutaneous T 53 Cerebril TM 53 MGd 53 androgen receptor AR 53 NASDAQ CXSP announced 53 faropenem medoxomil 53 URG# 53 HDL Selective Delipidation 53 Gentamicin Surgical Implant 53 lymphoid malignancies 53 Pyridorin 53 candidate REP# 53 hyaluronidase enzyme 53 dacetuzumab SGN 53 Dalbavancin 53 website http:/www.celsion.com 53 Somatuline Autogel 53 Toremifene 53 SPRIX ® 53 Ophena TM 53 factor TNF receptor 53 midstage studies 53 multiple myeloma MM 53 Entereg TM 53 intradermal injection 53 vaginal lidocaine 53 AERx iDMS 53 Phase III Trial 53 Familial Adenomatous Polyposis FAP 53 immunomodulator 53 oral talactoferrin 53 novel orally administered 53 cetrorelix pamoate 53 Kosan dependence 53 antifungal therapy 53 oral picoplatin 53 Drug Eluting Stent System 53 Actilon 53 Nabi HB Intravenous 53 rilonacept 53 ICA # 53 DURIN TM 53 prodrugs 53 Fodosine TM 53 lumiliximab 53 Fortovase 53 Application BLA 53 MT# MEDI 53 Phase #b/#a 53 LibiGel ® 53 IMiDs R 53 Sapacitabine 53 vosaroxin 53 IMiDs 53 rALLy clinical trial 53 tafamidis 53 radiation sensitizer 53 Files Investigational 53 Aurexis 53 Silenor ® doxepin 53 Nasdaq PCYC 53 ® decitabine 53 REGENERX BIOPHARMACEUTICALS INC. 53 clevudine 53 zolpidem tartrate sublingual tablet 53 Oracea TM 53 STEDESA 53 sarcoma melanoma 53 Antigen Express website 53 thorough QT 53 steroid refractory GvHD 53 recurrent metastatic 53 OvaRex R 53 GLP1 agonist 52 Presents Positive 52 ZYBRESTAT TM 52 Granted Orphan Drug 52 Taiho Pharmaceutical 52 zileuton CR 52 Onconase 52 voreloxin 52 Phase IIa clinical 52 toenail onychomycosis 52 CCR5 antagonist 52 GLPG# 52 Mycograb 52 intravenous acetaminophen 52 registrational 52 vilazodone 52 Ostabolin C TM 52 Friedreich Ataxia FRDA 52 OTCQX QRXPY 52 pan Bcl 2 52 SILENOR ™ 52 Nexavar ® 52 biologic DMARD 52 pomalidomide 52 NEUGENE R 52 Prednisporin TM 52 gastrointestinal disorders characterized 52 Chemophase 52 Amigal TM 52 Vectibix panitumumab 52 dosing cohort 52 Completes Enrollment 52 remission induction 52 Nasdaq EPCT 52 ATPace TM 52 Gemifloxacin 52 lintuzumab 52 midstage clinical 52 Androxal ® 52 Phase 2a 52 Nanobody 52 Bendamustine 52 tramiprosate ALZHEMED TM 52 BrachySil TM 52 OMAPRO ™ 52 ANTEGREN 52 Laquinimod 52 anthracycline unless 52 TRA 2P 52 Pagoclone 52 Curaxin 52 Specifid 52 HepDirect prodrug 52 Targretin capsules 52 E1 INT TM 52 edifoligide 52 Vitrasert R 52 mesylate tablets 52 TransVax tm 52 ATryn ® 52 NMDA antagonist 52 CG# [003] 52 containing LABAs 52 Investigational Treatment 52 fallopian tube cancers 52 ELND# 52 ruxolitinib 52 forodesine hydrochloride 52 Raf kinase 52 ERBITUX therapy 52 cilengitide 52 HoFH 52 Shigamabs 52 inhaled AAT 52 Plenaxis TM 52 Aztreonam lysine 52 Amrubicin 52 Stavzor TM 52 subcutaneous formulation 52 Mesafem 52 Oxytrex TM 52 preclinical pharmacokinetic 52 Staphylococcus aureus Immune Globulin 52 punctal plug 52 KRN# 52 Cand5 52 novel MetAP 2 52 vemurafenib 52 Metastatic Melanoma 52 Mirapexin 52 FORADIL 52 RANK Ligand inhibitor 52 eosinophilic asthma 52 Tyzeka Sebivo 52 preclinical 52 HepaGam B TM 52 Clolar ® 52 advance Debio 52 Trofex 52 danazol 52 RIGScan CR 52 inhaled formulation 52 investigational pan BCR 52 exocrine pancreatic insufficiency EPI 52 ALN VSP Phase 52 ANAVEX #-# [001] 52 Orphan Drug Status 52 pivotal bioequivalence 52 Cellegesic 52 FACTIVE R gemifloxacin 52 PCA3 assay 52 mitotic kinesin 52 PEARL SC 52 IMiDs ® compound 52 REG1 Anticoagulation System 52 Inc. NASDAQ BPAX 52 Virium 52 Panzem 52 VALSTAR 52 Resten NG 52 treatmentof 52 canakinumab 52 mTOR inhibitor 52 ZEVALIN ® 52 immune modulatory 52 Pivotal Clinical Trial 52 tezampanel 52 markets Gelclair R 52 PD LID 52 Trovax 52 Somatuline Depot 52 XL# XL# XL# 52 Severe VOD 52 Poly ICLC 52 budesonide MMX ® 52 VITAL Trial 52 DSMB recommended 52 NeoLipid drug 52 prGCD 52 QNEXA ® 52 Corlux 52 relapsed refractory multiple myeloma 52 drug figitumumab 52 delivers fluocinolone acetonide FA 52 Velaglucerase Alfa 52 idiopathic thrombocytopenic purpura 52 Shigamabs R 52 SUCCEED trial 52 Extina 52 Bioral Amphotericin B 52 Phase #/#a 52 Parathyroid Hormone PTH1 52 5 HT3 receptor 52 evaluating Actimmune 52 Nasdaq OSCI 52 Orphan Drug status 52 Diamyd r 52 polyneuropathy HIV DSP 52 Chaim Lebovits President 52 LOMUCIN 52 recurrent NSCLC